false
0001892025
0001892025
2026-07-14
2026-07-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event
reported): July 14, 2026
Optimus Healthcare Services, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| Florida |
|
333-261849 |
|
65-0181535 |
|
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
|
1400 Old Country Road, Suite 306
Westbury, New York |
|
11590 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
(516) 806-4201
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: None.
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.05 Costs Associated with Exit or Disposal Activities.
As disclosed
in our Current Report on Form 8-K filed on April 16, 2025, on April 14, 2025 (the “Effective Date”), Optimus Healthcare Services,
Inc. (the “Company”) entered into the fourth amendment to the forbearance agreement (the “Amendment”) by and among
the Company and Arena Investors, LP, as agent (“Agent”) for the purchasers of the Company’s senior secured convertible
notes (collectively, the “Purchasers”) issued in May 2021 (the “May 2021 Notes”) and June 2022 (the “June
2022 Notes” and collectively with the May 2021 Notes, the “Notes”), pursuant to which, among other things, (i) Section
1(b) of the Forbearance Agreement was amended such that the Agent and the Purchasers agreed to forbear from exercising their rights
and remedies with respect to the Specified Events of Default (as defined in the Amendment) under the Notes until that date which is the
earliest to occur of: (a) April 30, 2025; (b) the date on which any event of default under the Notes (other than the Specified Events
of Default) occurs; and (c) the date on which the Company or any of its subsidiaries fails to comply with any term set forth in the Forbearance
Agreement; (ii) the deadline for the consummation of the Qualified Subsequent Financing restructuring milestone was amended from February
28, 2025 to April 30, 2025 and (iii) the definition of “Filing Date” in the Amended and Restated Registration Rights
Agreements (as defined in the Amendment) was amended such that the Company agreed to file a registration statement for such securities
on the 45th calendar day following the date the Company’s independent public accountants have completed their audit for
the fiscal year ended December 31, 2024 and the Company has filed its Annual Report on Form 10-K including such financial statements,
or if later, July 31, 2025.
As
previously announced in our Current Report on Form 8-K filed with the SEC on June 9, 2025, Management started a review of all its strategic
alternatives, inclusive of potential new investors, an extension of time under its current Forbearance Agreement, and if the above were
unsuccessful, the potential sale or curtailment of some or all of its operations. As of the date of our Current Report on Form 8-K filed
with the SEC on September 11, 2025, the Board had completed its strategic review of the Company and determined to initiate the wind down
of the Company’s operations given there were no other alternatives to provide the Company ongoing cash to operate its business and
it was unable to cure the Specified Defaults under the Notes.
In
connection with these decisions, the Board approved certain wind down initiatives, including a reduction in force. The Company has maintained
a core group of employees necessary to implement an orderly wind down of the Company, including all regulatory aspects of transitioning
patient care under existing oncology trials, and support its efforts to maximize the value of the Company’s remaining business and
assets. In connection with the wind down, the Company paid in full the outstanding balance on a secured loan from JP Morgan Chase Bank.
On
July 14, 2026, with the unanimous approval of the Company’s Board of Directors, the Company entered into an agreement with its first
priority secured lender (Agent and Purchasers) to settle its outstanding secured debt of $4.4 million plus accrued interest on the Notes
and resolve all outstanding claims by Agent and Purchasers under those Notes. As part of the agreement, the Company has agreed to deliver
to Agent and Purchasers the remaining cash of the Company, after payment of operating expenses necessary to effectuate the wind down.
Upon the final payment to Agent on July 31, 2026, Agent and Purchasers will deem the Notes terminated, and the Company and its officers
and directors will receive a release from Agent and Purchasers.
After
its final payment to Agent and Purchasers on or about July 31, 2026, the Company’s operations will cease and its bank accounts will
be closed.
In
conjunction with its final wind down steps, all of the Company’s Directors and Officers will resign effective August 5, 2026.
Cautionary Notes Regarding
Forward Looking Statements
This Current Report on Form 8-K may contain forward-looking statements regarding future events and our future results that are subject
to the safe harbors created under the Private Securities Litigation Reform Act of 1995. These statements reflect the beliefs and assumptions
of the Company’s management as of the date hereof. Words such as “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,”
“plan,” “project,” “seek,” “should,” “target,” “will,” “would,”
variations of such words, and similar expressions are intended to identify forward-looking statements, including among others, statements
regarding potential strategic alternatives, including capital raises, sale transaction options, restructuring activities and other alternatives.
Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions
that are difficult to predict. The Company’s actual results could differ materially and adversely from those expressed in or contemplated
by the forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, statements concerning
the Board’s strategic review; the perceived benefits and timing of the wind down; the Company’s plans and expected timing
with respect to the reduction in workforce; the timeline in which the Company expects to be able to wind down its operations; and other
risk factors contained in the Company’s SEC filings available at www.sec.gov, including without limitation, the Company’s
annual report on Form 10-K, quarterly reports on Form 10-Q and subsequent filings. In addition, additional or unforeseen effects from
the global economic climate may give rise to or amplify many of these risks. Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date on which they are made. There can be no assurance that the actual results
or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences
to, or effects on, the Company. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements will
be achieved. The Company undertakes no obligation to update or revise any forward-looking statements for any reason.
| Exhibit No. |
|
Description |
| |
|
|
| 10.1 |
|
Wind-Down and Distribution Agreement, dated July 14, 2026 |
|
104 |
|
Cover Page Interactive Data File (embedded
within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| OPTIMUS HEALTHCARE SERVICES, INC. |
|
| |
|
| By: |
/s/ Cliff Saffron |
|
| |
Cliff Saffron |
|
| |
Interim Chief Executive Officer and General Counsel |
|
| |
|
| Dated: July 17, 2026 |
|